Intravenous immunoglobulin for the treatment of Crohn's disease

Autoimmunity Reviews
Moshe RogosnitzkyDaniel Holt

Abstract

Crohn's disease (CD) is a debilitating condition which still requires improvement in its management. There is a need for alternatives to anti-tumour necrosis factor drugs which are costly and beneficial in less than 50% of patients. Intravenous immunoglobulin (IVIG) has been used in the management of aminosalicylate- and steroid-resistant CD for more than 20 years, although the published literature available is limited. A literature search identified 17 relevant publications since 1969, including five case reports of single patients, two abstracts, three conference papers, one review paper and six book or journal articles. No randomised controlled trials of IVIG in CD have been published. A review of the evidence identified indicates that IVIG can induce a rapid and significant improvement in aminosalicylate- and steroid-resistant CD, often within days of the initial administration. Data from longer-term studies show that maintenance of remission over the medium term is also possible. These encouraging findings provide a rationale for the initiation of larger randomised controlled trials of IVIG in CD with the aim of providing further treatment options for this difficult-to-manage condition.

References

Mar 1, 1990·Annals of Internal Medicine·P KnoflachM M Eibl
Jan 1, 1986·Vox Sanguinis·H Cottier, A Hässig
Dec 9, 2010·Alimentary Pharmacology & Therapeutics·S C NgJ J Y Sung
Mar 8, 2011·Autoimmunity Reviews·Mohan S MaddurJagadeesh Bayry
Jul 7, 2011·Clinical Reviews in Allergy & Immunology·Gisele Zandman-GoddardYehuda Shoenfeld
Aug 26, 2011·Current Pharmaceutical Design·Uriel KatzGisele Zandman-Goddard
Aug 26, 2011·Autoimmunity Reviews·Mohan S MaddurJagadeesh Bayry
Feb 22, 2012·Autoimmunity Reviews·Srini V Kaveri

❮ Previous
Next ❯

Citations

Sep 4, 2014·Autoimmunity Reviews·Maria Giovanna DanieliArmando Gabrielli
Aug 31, 2014·Autoimmunity Reviews·Maria Giovanna DanieliFrancesco Logullo
Sep 17, 2014·Expert Opinion on Biological Therapy·Kyungmin LeeC Stephen Foster
Jul 29, 2016·PloS One·Wilhelmina M C TimmermansMenno C van Zelm
Oct 19, 2016·Digestive Diseases and Sciences·Nicholas HortonBo Shen
Feb 11, 2015·Autoimmunity Reviews·I MarieP Ducrotte
May 17, 2014·Inflammatory Bowel Diseases·Umang JainAndrew W Stadnyk
Apr 22, 2015·Inflammatory Bowel Diseases·Irena Trbojević AkmačićUNKNOWN IBD-BIOM Consortium
Jun 27, 2013·Pediatric Blood & Cancer·Angela D Trobaugh-LotrarioJames H Feusner
Dec 30, 2014·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Joana SimoesMaria Jose Cuadrado
Dec 30, 2014·Clinical and Experimental Immunology·M G Danieli, Y Shoenfeld
Dec 18, 2015·The American Journal of Gastroenterology·Brian P McAllisterDiane M Paskey
Feb 27, 2017·Journal of Clinical Immunology·Sara BarmettlerJolan E Walter
Apr 30, 2019·Frontiers in Immunology·Tomas Castro-Dopico, Menna R Clatworthy
Dec 30, 2014·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·J DelaneyA Engel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.